UNICANCER

🇧🇷Brazil

Country: 🇧🇷Brazil

Ownership: Private

Established: 1964-01-01

Employees: 101

Market Cap: -

Website: http://www.unicancer.fr

Clinical Trials

My Personalized Breast Screening

Not Applicable

Active, not recruiting

Conditions: Breast Screening

Interventions: Other: Mammogram
Other: Ultrasound
Other: MRI
Other: Tomosynthesis

First Posted Date: 2018-09-14

Last Posted Date: 2023-08-29

Lead Sponsor: UNICANCER

Target Recruit Count: 53142

Registration Number: NCT03672331

Locations: 🇬🇧
Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom
🇧🇪
Institut Jules Bordet, Bruxelles, Belgium
🇮🇱
Assuta Medical Center Ramat HaHayal, Tel Aviv, Israel

and more 3 locations

Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients

Phase 2

Active, not recruiting

Conditions: Osteosarcoma

Interventions: Drug: Mifamurtide
Combination Product: EI or M-API regimen depending on patient age

First Posted Date: 2018-08-22

Last Posted Date: 2024-11-08

Lead Sponsor: UNICANCER

Target Recruit Count: 60

Registration Number: NCT03643133

Locations: 🇫🇷
CHU de Nice - Service d'oncologie hématologie pédiatrique, Nice, France
🇫🇷
CHU Toulouse - Hôpital des Enfants - Service d'Hémato-Immuno-Oncologie, Toulouse, France
🇫🇷
CHU de Caen - Service d'oncologie hématologie pédiatrique, Caen, France

and more 28 locations

Oligometastases of the LIVer Treated With Chemotherapy With ou Without Extracranial Stereotactic Body Radiation Therapy in Patients With Colorectal Cancer

Not Applicable

Withdrawn

Conditions: Liver Metastases
Colorectal Cancer

Interventions: Radiation: SBRT
Drug: Chemotherapy

First Posted Date: 2018-05-22

Last Posted Date: 2019-05-22

Lead Sponsor: UNICANCER

Registration Number: NCT03532204

Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours

Phase 1

Completed

Conditions: Cervix Cancer
Breast Cancer
Head and Neck Cancer
Advanced Solid Tumours
Prostate Cancer

Interventions: Drug: Durvalumab + Tremelimumab + metronomic Vinorelbine

First Posted Date: 2018-05-08

Last Posted Date: 2025-01-15

Lead Sponsor: UNICANCER

Target Recruit Count: 126

Registration Number: NCT03518606

Locations: 🇫🇷
Centre François Baclesse, Caen, France
🇫🇷
Centre Georges-François Leclerc, Dijon, France
🇫🇷
Centre Antoine Lacassagne, Nice, France

and more 6 locations

Efficacy of Repeat Stereotactic Radiation in Patients With Intraprostatic Tumor Recurrence

Not Applicable

Active, not recruiting

Conditions: Local Recurrence of Malignant Tumor of Prostate

Interventions: Radiation: Stereotactic Body Radiotherapy

First Posted Date: 2018-02-19

Last Posted Date: 2024-12-20

Lead Sponsor: UNICANCER

Target Recruit Count: 57

Registration Number: NCT03438552

Locations: 🇫🇷
Centre François Baclesse, Caen, France
🇫🇷
Centre Jean Perrin, Clermont-Ferrand, France
🇫🇷
Centre George François Leclerc, Dijon, France

and more 9 locations

Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists

Not Applicable

Active, not recruiting

Conditions: Head and Neck Squamous Cell Carcinoma
Non Small Cell Lung Cancer
Melanoma

Interventions: Procedure: Biopsy

First Posted Date: 2018-01-26

Last Posted Date: 2025-02-20

Lead Sponsor: UNICANCER

Target Recruit Count: 670

Registration Number: NCT03412058

Locations: 🇫🇷
Centre Hospitalier Inter. de Creteil, Créteil, France
🇫🇷
Institut Bergonie, Bordeaux, France
🇫🇷
Centre Oscar lambret, Lille, France

and more 16 locations

SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer, PI3K, Alpelisib

Interventions: Drug: Chemotherapy
Drug: Alpelisib

First Posted Date: 2017-12-29

Last Posted Date: 2022-11-28

Lead Sponsor: UNICANCER

Target Recruit Count: 31

Registration Number: NCT03386162

Locations: 🇫🇷
Institut Sainte-Catherine, Avignon, France
🇫🇷
Chd Vendee, La Roche Sur Yon, France
🇫🇷
CHU Dupuytren, Limoges, France

and more 11 locations

Study on Androgen Receptor and Triple Negative Breast Cancer

Phase 2

Completed

Conditions: Triple Negative and Androgen Receptor Positive
Breast Cancer Female

Interventions: Drug: Darolutamide
Drug: Capecitabine

First Posted Date: 2017-12-26

Last Posted Date: 2022-11-21

Lead Sponsor: UNICANCER

Target Recruit Count: 94

Registration Number: NCT03383679

Locations: 🇫🇷
Centre François Baclesse, Caen, France

Adjuvant Radiotherapy in Patients With Pathological High-risk Bladder Cancer (GETUG-AFU 30)

Not Applicable

Active, not recruiting

Conditions: Patients With High-risk MIBC

Interventions: Radiation: pelvic radiotherapy

First Posted Date: 2017-11-06

Last Posted Date: 2024-12-04

Lead Sponsor: UNICANCER

Target Recruit Count: 81

Registration Number: NCT03333356

Locations: 🇫🇷
ICO Paul Papin, Angers, France
🇫🇷
Institut Bergonie, Bordeaux, France
🇫🇷
Centre Francois Baclesse, Caen, France

and more 14 locations

A Patient Consensus for the Research in Supportive Care in French Cancer Care Centers: the CyPRES Project

Completed

Conditions: Cancer Patients

First Posted Date: 2017-10-25

Last Posted Date: 2021-11-04

Lead Sponsor: UNICANCER

Target Recruit Count: 604

Registration Number: NCT03320161

Locations: 🇲🇶
Ligue Nationale Contre le Cancer - Comité de la martinique, Fort de France, Martinique
🇫🇷
Ligue Nationale Contre le Cancer - Comité du Maine-et-Loire, Angers, France
🇫🇷
Ligue Nationale Contre le Cancer - Comité de Charente, Angoulême, France

and more 54 locations

Home Terms & Conditions Privacy Policy